Advertisement
Singapore markets closed
  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     
  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • FTSE 100

    7,835.94
    -41.11 (-0.52%)
     
  • Bitcoin USD

    65,352.96
    +3,071.17 (+4.93%)
     
  • CMC Crypto 200

    1,337.69
    +25.07 (+1.95%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Gold

    2,394.10
    -3.90 (-0.16%)
     
  • Crude Oil

    82.17
    -0.56 (-0.68%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     
  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     
  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Analyzing Merck’s Revenue in 1Q18

Analyzing Merck’s Revenue in 1Q18

Merck (MRK), one of the largest pharmaceutical companies worldwide, is classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company reported its 1Q18 results on May 1. During the quarter, Merck surpassed analysts’ EPS (earnings per share) estimate of $1, but missed their revenue estimate of $10.1 billion, reporting EPS of $1.05 on revenue of $10.0 billion.